Navigation Links
TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
Date:5/6/2008

SAN DIEGO, May 6 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a leading provider of custom nucleic acid-based compounds, has been awarded a Phase II Small Business Innovation Research (SBIR) grant of approximately $750,000 to continue its investigation of modified dNTPs to improve the fidelity of PCR reactions. Phase I studies demonstrated that TriLink's unique dNTP modifications enhanced PCR performance by increasing amplicon formation while reducing off-target amplicon formation. In the second phase of the program, TriLink will look to further expand upon Phase I studies to develop novel solutions for endpoint PCR, real-time PCR, multiplex PCR, fast PCR, and more advanced PCR applications. TriLink will also optimize the synthetic route for scale-up of the modified dNTPs and will develop robust PCR assay recommendations in preparation for commercialization of the technology in early 2009. This is the third Phase II grant TriLink has been awarded.

"We believe that this novel approach to improving PCR fidelity complements our CleanAmp(TM) product line very nicely," said Dr. Richard Hogrefe, CEO and President of TriLink. "Now we offer modified primers and modified dNTPs. The CleanAmp(TM) Primers will solve specific assay issues whereas the modified dNTPs will be a more general solution. Either product will provide a very cost effective solution when compared to the modified enzymes available on the market."

About TriLink

TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, nucleoside triphosphates and synthesis reagents for research and diagnostic laboratories. In addition, it offers radiolabeling services, custom chemistry, contract research services and GMP production facilities for oligos and small molecules. TriLink's solutions help advance drug discovery and biomedical research. For more information visit http://www.trilinkbiotech.com or contact:

TriLink BioTechnologies

Shawna Leaver, 858-546-0004

sleaver@trilinkbiotech.com


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
10. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CITY , March 29, 2017  Bodycad ... and Drug Administration (FDA) 510(k) clearance for its ... of this truly personalized orthopaedic restoration. Bodycad is ... for a joint reconstruction implant system. ... to optimize personalized restoration of the patient,s unique ...
(Date:3/29/2017)... Global intravenous (IV) iron and oral iron market ... at a CAGR of 5%. Iron drugs ... treat anemia or other iron deficiencies. Oral iron supplements are ... in some cases, oral administrations are not capable of maintaining ... therapy comes into the picture. Global Intravenous (IV) ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare partner ... with prominent executives from both inside and outside the cannabis industry. , Joining ... , who has more than twenty years of business leadership and investment experience in ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
Breaking Medicine News(10 mins):